India’s Biocon Moves Forward With Oral Insulin After Encouraging Phase II Results
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In what is seen as a significant development for the company, Indian biotechnology firm Biocon presented encouraging Phase II data on its experimental oral insulin drug coded IN-105 at the European Association for the Study of Diabetes meeting being held at Rome